Reports
Sale
Global Neuroendocrine Tumours Treatment Market Share, Size, Analysis, Trends, Forecast: By Treatment Type: Targeted Therapy, Chemotherapy, Somatostatin Analogues (SSAs); By Indication: Gastrointestinal NET, Lung NET, Others; By End-Use; Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2023-2028
Global Neuroendocrine Tumours Treatment Market Outlook
The global neuroendocrine tumours treatment market would likely grow at a CAGR of 10.1% during 2023-2028. The number of patients with neuroendocrine tumours is increasing (generally with metastatic disease, and warranting systemic therapy) across the globe. Asia, North America and Europe are likely to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Growth Likely to be Driven by Increasing Occurrence of Neuroendocrine Tumours Across the Globe
Neuroendocrine tumours refer to rare tumours that may occur in several different organs of the body. Symptoms of neuroendocrine tumours largely depend on tumours’ location in the body and the hormones these produce. As an example, a gastrointestinal neuroendocrine tumour may lead to symptoms such as diarrhoea, constipation or stomach aches; pulmonary neuroendocrine tumours may give birth to wheezing or incessant cough; some tumours may cause the release of very large amounts of hormones into the bloodstream. Such tumours are called "functioning tumours" and may lead to symptoms including flushing, diarrhoea, wheezing, cramps, hypoglycaemia, changes in blood pressure, and heart problems.
Procedures and tests carried out to diagnose a neuroendocrine tumour may include a physical examination (including looking for swollen lymph nodes or indications that a tumour is releasing excess hormones), tests to identify release of excess hormones (including urine or blood tests to identify excess hormones generated by neuroendocrine tumours), imaging tests [including MRI, CT, ultrasound, to generate images of the tumour; for neuroendocrine tumours, positron emission tomography (PET) may be employed), and biopsy. Additional tests may be carried out if there is a risk that the neuroendocrine tumour may have spread to other parts of the body.
Treatment for neuroendocrine tumour depends on the type and location of tumour, and the symptoms and excess hormones released by the tumour. Treatment options include chemotherapy, surgery, peptide receptor radionuclide therapy (PRRT), targeted drug therapy, radiation therapy, and medications to regulate excess hormones.
Innovations in Treatment Systems Likely to Boost Market Growth
Leading companies are engaged in developing innovative solutions for the treatment of neuroendocrine tumours. For example, in 2018, Novartis AG announced that new drug application (NDA) of Advanced Accelerator Applications (a subsidiary of Novartis Groupe S.A.) obtained US FDA approval for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including midgut, foregut, and hindgut neuroendocrine tumors, in adults. Lutathera, was a first-in-class drug (a drug employing a novel and unique mechanism of action to treat a medical condition) and the first available FDA-approved Peptide Receptor Radionuclide Therapy (PRRT). Such developments are likely to boost the global neuroendocrine tumours treatment market.
Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By treatment type, the market is segmented into:
- Targeted Therapy
- Chemotherapy
- Somatostatin Analogues (SSAs)
By indication, the market is divided into:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others
By end use, the market is divided into:
- Hospitals
- Clinics
- Others
By region, the market is segmented into:
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Market
The report offers an extensive assessment of major players in the global neuroendocrine tumours treatment market; it evaluates their capability, observes latest occurrences such as mergers and acquisitions, capacity expansions, and plant turnarounds:
- Pfizer Inc
- Novartis AG
- Ipsen Pharma
- Abbvie Inc.
- AVEO Pharmaceuticals, Inc
- Others
Using SWOT analysis and Porter’s Five Forces model, the EMR report offers deep insights into the industry.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Indication |
|
| Breakup by End-Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Neuroendocrine Tumors Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Neuroendocrine Tumours Treatment Historical Market (2018-2022)
8.3 Global Neuroendocrine Tumours Treatment Market Forecast (2023-2028)
8.4 Global Neuroendocrine Tumours Treatment Market by Treatment Type
8.4.1 Targeted Therapy
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Chemotherapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Somatostatin Analogues (SSAs)
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.5 Global Neuroendocrine Tumours Treatment Market by Indication
8.5.1 Gastrointestinal NET
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Lung NET
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Pancreatic NET
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Others
8.6 Global Neuroendocrine Tumours Treatment Market by End-Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Clinics
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Others
8.7 Global Neuroendocrine Tumours Treatment Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2022)
8.7.4.3 Forecast Trend (2023-2028)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2022)
8.7.5.3 Forecast Trend (2023-2028)
9 North America Neuroendocrine Tumours Treatment Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Neuroendocrine Tumours Treatment Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Neuroendocrine Tumours Treatment Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Neuroendocrine Tumours Treatment Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Neuroendocrine Tumours Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Pfizer Inc
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Novartis AG
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Ipsen Pharma
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Abbvie Inc.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 AVEO Pharmaceuticals, Inc
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Figures and Tables
1. Global Neuroendocrine Tumours Treatment Market: Key Industry Highlights, 2018 and 2028
2. Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Treatment Type (USD Million), 2018-2022
3. Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Treatment Type (USD Million), 2023-2028
4. Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Indication (USD Million), 2018-2022
5. Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Indication (USD Million), 2023-2028
6. Global Neuroendocrine Tumours Treatment Historical Market: Breakup by End Use (USD Million), 2018-2022
7. Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by End Use (USD Million), 2023-2028
8. Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Region (USD Million), 2018-2022
9. Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Region (USD Million), 2023-2028
10. North America Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
11. North America Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Europe Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
13. Europe Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Asia Pacific Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
15. Asia Pacific Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Latin America Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
17. Latin America Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Middle East and Africa Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
19. Middle East and Africa Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Global Neuroendocrine Tumours Treatment Market Structure
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER